Some studies have shown that in vivo administration of PPAR-γ agonist substances can stimulate adipocyte differentiation and fatty acid oxidation, promote weight loss, and reduce adipocytes and adipose tissue, thus achieving an anti-obesity effect [20,21]. The gene discussed is PPARG; the disease is obesity disorder.